Global Thrombotic Thrombocytopenic Purpura (TTP) Market - 2023-2030

Global Thrombotic Thrombocytopenic Purpura (TTP) Market - 2023-2030

The global thrombotic thrombocytopenic purpura (TTP) market reached US$ 1.0 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 1.4 billion by 2030. The global thrombotic thrombocytopenic purpura (TTP) market is expected to exhibit a CAGR of 4.7% during the forecast period (2023-2030).

TTP usually emerges unexpectedly and stays for days or weeks, though it can persist for months. TTP can even push red blood cells to shatter separated quickly than the normal body can substitute them. This directs to an infrequent condition of anemia called hemolytic anemia. TTP can be deadly. Without therapy, it can induce long-term issues, like brain injury or a stroke.

The growing number of cases, rising market developments, increasing number of clinical research activities, and growth in research funding along with additional elements are expected to promote the global thrombotic thrombocytopenic purpura market growth in the forecast period.

Market Dynamics

Increasing Clinical Research Activities Drive The Growth Of The Thrombotic Thrombocytopenic Purpura (TTP) Market.

The increasing clinical research activities are expected to drive the global thrombotic thrombocytopenic purpura (TTP) market growth in the forecast period. For instance, according to clinicaltrials.gov, presently 2 phase one interventional studies are active, 2 phase two interventional studies are active, and 4 phase three interventional studies are active. Moreover, 106 observational studies are present out of which 1 is active 24 are currently recruiting and 8 are not yet recruiting.

Moreover, in January 2023, Takeda publicized the evidence from a pre-planned interim analysis of a pivotal Phase 3 study backs the effectiveness and safeness of TAK-755 as enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP), an ultra-rare sub-type of thrombotic thrombocytopenic purpura (TTP), an infrequent, chronic and debilitating blood clotting condition induced by a deficit in ADAMTS13 protease.

The Increasing Funding From The Government Is Expected To Present The Global Thrombotic Thrombocytopenic Purpura (TTP) Market With Growth Opportunities.

The increasing awareness and funding for research and support are estimated to present the global market with prospective growth opportunities in the upcoming years. For instance, the Answering TTP Foundation's TTP Day gets the international TTP community together to introduce budgets to fund investigation, awareness, and aid. Participants utilize their customized fundraising page to increase budgets for their occasion. Registrants either walk or fundraise another way to be a component of this multinational campaign getting small communities jointly to be components of something significant.

Moreover, in December 2021, the National Institute of General Medical Sciences, part of the National Institutes of Health lately granted a five-year USD 1.67 million budget to Assistant Professor of Biochemistry Joshua Muia, Ph.D., who is expecting his investigation into two tiny enzymes can aid in pinpoint and perhaps treat an infrequent blood condition and the most typical type of heart condition.

The High Cost Of The Thrombotic Thrombocytopenic Purpura (TTP) Treatment is Estimated To Hamper The Global Thrombotic Thrombocytopenic Purpura (TTP) Market During The Forecast Period.

The high cost of the thrombotic thrombocytopenic purpura (TTP) treatment makes it difficult for the low-income population to opt for the treatment reducing the market demand and thereby its growth in the forecast period. For instance, according to an article published in August 2021, by the American Journal of Managed Care, for plasma exchange or rituximab or caplacizumab, per treatment cost is approximately USD 7,000. Specifically for plasma exchange and caplacizumab, the patient requires to take them daily at least a dose for 1 course.

COVID-19 Impact Analysis.

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis.

The Russia-Ukraine conflict is thought to hold a minimal influence on the global thrombotic thrombocytopenic purpura (TTP) market, as there is a low incidence of conditions and a lack of primary market players in this region. Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of fundamental materials are expected to minimally impact the global thrombotic thrombocytopenic purpura (TTP) market growth in the forecast period.

Segment Analysis

The global thrombotic thrombocytopenic purpura (TPP) market is segmented based on type, treatment, end-user, and region.

The Inherited TTP Type Segment is Estimated to Dominate the Global Thrombotic Thrombocytopenic Purpura (TTP) Market.

With the increasing efforts to better understand the condition and new drug developments the inherited type of TTP is estimated to hold about 38.4% of the global market by 2030. For instnace, the Hereditary Thrombotic Thrombocytopenic Purpura Registry is the largest global Registry for cases with hereditary/congenital thrombotic thrombocytopenic purpura (hTTP), also comprehended as Upshaw-Schulman syndrome. The primary objective is to gather data regarding hTTP from as considerable patients and their families as conceivable. This aids in sounder comprehension of the representations and the unmet requirements of these patients associated with such rare conditions.

In June 2023, analogized to plasma-based treatments, the exclusive recombinant ADAMTS13 protein in the product showed substantial effectiveness in a trial for congenital thrombotic thrombocytopenic purpura (cTTP), Takeda demonstrated. Moreover, in May 2023, Takeda, the U.S. Food and Drug Administration (FDA) received Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement treatment for the therapy of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 depletion condition.

Geographical Analysis

Europe is Estimated to Hold 26.8% of the Market Share Owing to the Growing Cases of Chronic Conditions in this Region.

Owing to the increasing prevalence of thrombotic thrombocytopenic purpura (TTP) and the presence of distinct organizations working to raise funding and spread awareness about thrombotic thrombocytopenic purpura (TTP), the European thrombotic thrombocytopenic purpura (TTP) market is estimated to hold about 26.8% of the global market share.

For instance, acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan condition with a registered yearly incidence between 1.5 and 6.0 cases per million in Europe and especially affecting otherwise young and healthy adults aged 40 years on a standard. Moreover, the Good Grief Trust in the UK supports thrombotic thrombocytopenic purpura (TTP) patients.

Competitive Landscape

The major global players in the market include Pfizer Inc, F. Hoffmann-La Roche Ltd, Aspen Holdings, Fresenius Kabi AG, Novartis AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited., CSL Limited and Mylan N.V., among others.

Why Purchase the Report?
• To visualize the global thrombotic thrombocytopenic purpura (TTP) market segmentation based on type, treatment, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of thrombotic thrombocytopenic purpura (TTP) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Type mapping available in Excel consisting of key Types of all the major players.

The global thrombotic thrombocytopenic purpura (TTP) market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies